文献速递肝病

纳莫德诺松治疗非酒精性脂肪性肝病的2期随机双盲试验

Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis.
PubMed 文献 · Aliment Pharmacol Ther · 2021-10-20

这项2期随机双盲试验纳入60例NAFLD患者(ALT≥60 IU/L),按1:1:1随机接受纳莫德诺松12.5 mg每日两次、25 mg每日两次或安慰剂治疗12周(随访16周)。主要终点为治疗12周后血清ALT。结果显示ALT和AST呈剂量依赖性下降,25 mg组第16周ALT正常化率显著高于安慰剂(36.8% vs 10.0%,P=0.038),药物耐受性良好。

要点

  • 纳莫德诺松25 mg每日两次可剂量依赖性降低ALT和AST。
  • 第16周ALT正常化率25 mg组36.8%,安慰剂组10.0%(P=0.038)。
  • 两种剂量均耐受良好,未出现药物相关严重不良事件。

核心结论

  • A3腺苷受体是有效靶点,纳莫德诺松25 mg每日两次安全并显示出疗效信号。

研究设计与样本

  • 2期随机双盲试验纳入60例NAFLD患者(ALT≥60 IU/L),按1:1:1随机分为纳莫德诺松12.5 mg每日两次组(n=21)、25 mg每日两次组(n=19)和安慰剂组(n=20),治疗12周,总随访16周。

主要发现

  • 血清ALT随纳莫德诺松治疗呈剂量依赖性下降,25 mg组第12周较基线变化与安慰剂比较P=0.066。
  • 血清AST呈剂量依赖性下降,25 mg组第12周较基线变化与安慰剂比较P=0.03。
  • 第12周ALT正常化率25 mg组31.6%、安慰剂组20.0%(P=0.405);第16周分别为36.8%和10.0%(P=0.038)。
  • A3AR表达水平在各研究组间随时间保持稳定。

关键数值与推荐

  • 主要疗效终点为治疗12周后血清ALT。
  • 25 mg每日两次组第12周ALT较基线变化与安慰剂比较P=0.066,AST较基线变化P=0.03。
  • 第16周ALT正常化率25 mg组36.8% vs 安慰剂组10.0%(P=0.038)。

临床怎么用

  • 纳莫德诺松25 mg每日两次可能作为NAFLD伴ALT升高患者的潜在治疗选择,但需进一步验证。

局限性

  • 样本量较小(共60例),研究为2期探索性试验。
  • 主要终点ALT变化在25 mg组与安慰剂比较未达统计学显著性(P=0.066)。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Namodenoson, an A3 adenosine receptor (A3AR) agonist, improved liver function/pathology in non-alcoholic steatohepatitis (NASH) preclinical models. AIM: To evaluate the efficacy and safety of namodenoson for the treatment of non-alcoholic fatty liver disease (NAFLD) with or without NASH METHODS: This phase 2 study included 60 patients with NAFLD (ALT ≥60 IU/L) who were randomised (1:1:1) to oral namodenoson 12.5 mg b.d. (n = 21), 25 mg b.d. (n = 19), or placebo (n = 20) for 12 weeks (total follow-up: 16 weeks). The main efficacy endpoint involved serum ALT after 12 weeks of treatment. RESULTS: Serum ALT decreased over time with namodenoson in a dose-dependent manner. The difference between change from baseline (CFB) for ALT in the namodenoson 25 mg b.d. arm vs placebo trended towards significance at 12 weeks (P = 0.066). Serum AST levels also decreased with namodenoson in a dose-dependent manner; at 12 weeks, the CFB for 25 mg b.d. vs placebo was significant (P = 0.03). At Week 12, 31.6% in the namodenoson 25 mg b.d. arm and 20.0% in the placebo arm achieved ALT normalisation (P = 0.405). At week 16, the respective rates were 36.8% and 10.0% (P = 0.038). A3AR expression levels were stable over time across study arms. Both doses of namodenoson were well tolerated with no drug-emergent severe adverse events, drug-drug interactions, hepatotoxicity, or deaths. Three adverse events were considered possibly related to study treatment: myalgia (12.5 mg b.d. arm), muscular weakness (25 mg b.d. arm), and headache (25 mg b.d. arm). CONCLUSION: A3AR is a valid target; namodenoson 25 mg b.d. was safe and demonstrated efficacy signals (ClinicalTrials.gov #NCT02927314).

来源:Aliment Pharmacol Ther,查看原文。版权归原作者所有。

引用

  1. Safadi R, Braun M, Francis A, et al. Randomised clinical trial: A phase 2 double-blind study of namodenoson in non-alcoholic fatty liver disease and steatohepatitis. Aliment Pharmacol Ther. 2021. PMID: 34671996. doi:10.1111/apt.16664

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。